ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 04/04/23

2023-04-04 08:18:16 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) will receive a $40M milestone payment from Takeda Pharmaceutical ( NYSE: TAK ) as the Japanese patient dosed the first patient in a phase 3 trial of fazirsiran to treat alpha-1 antitrypsin deficiency associa...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda’s (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinical study of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency associated liver disease (AATD-LD). The sta...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $30 million milestone payment from GSK (LSE/NYSE: GSK) following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference (RNAi) therapeutic for the treatment...

2023-04-03 04:12:14 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Bitcoin, AMD, and Meta propelled my portfolio to all-time highs and market-beating return...

2023-03-22 07:44:35 ET Liver disease drug developer 89bio ( NASDAQ: ETNB ) added ~47% on Wednesday after announcing topline data from its Phase 2b ENLIVEN trial for pegozafermin in patients with nonalcoholic steatohepatitis (NASH). The trial involved 219 patients who wer...

2023-03-20 08:23:13 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) added ~7% in the pre-market Monday after announcing that the FDA issued Fast Track designation for its RNAi therapeutic ARO-APOC3 for reducing triglycerides in adults with familial chylomicronemia syndrome (...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designa...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston. A webcast link will be available on the E...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The complement system is a part of the body's immune system. According to the company ARO...